BRISTOL MYERS SQUIBB
๐ซ๐ทFrance
- Country
- ๐ซ๐ทFrance
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 266
- Registration Number
- NCT04567615
- Locations
- ๐ง๐ท
Local Institution - 0016, Barretos, SAO Paulo, Brazil
๐ฆ๐ทLocal Institution - 0010, Ciudad de Buenos Aires, Buenos Aires, Argentina
๐ฆ๐ทLocal Institution - 0019, Buenos Aires, Distrito Federal, Argentina
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986337 When Taken by Mouth by Healthy Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 26
- Registration Number
- NCT04550195
- Locations
- ๐ณ๐ฑ
ICON Plc (PRA Health Sciences) - Netherlands, Groningen, Netherlands
A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France
Active, not recruiting
- Conditions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 362
- Registration Number
- NCT04550247
- Locations
- ๐ซ๐ท
Local Institution, Lille, France
A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT04540705
- Locations
- ๐ฉ๐ช
Local Institution - 0044, Munich, Germany
๐บ๐ธLocal Institution - 0001, Saint Louis, Missouri, United States
๐ฉ๐ชLocal Institution - 0040, Jena, Germany
A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 56
- Registration Number
- NCT04536961
- Locations
- ๐ฌ๐ง
Quotient Sciences Miami, Nottingham, United Kingdom
Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy Participants
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT04515628
- Locations
- ๐บ๐ธ
ICON (LPRA) - Salt Lake, Salt Lake City, Utah, United States
A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 101
- Registration Number
- NCT04513522
- Locations
- ๐ฎ๐ณ
Local Institution - 0002, Karnataka, India
๐ฎ๐ณLocal Institution - 0007, New Delhi, Delhi, India
๐ฎ๐ณLocal Institution - 0011, Trivandrum, Kerala, India
A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy
Active, not recruiting
- Conditions
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 698
- Registration Number
- NCT04500535
- Locations
- ๐ซ๐ท
Local Institution - 0001, Paris Cedex 5, France
Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT04495010
- Locations
- ๐ฌ๐ง
Local Institution, Sutton, United Kingdom
A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 13
- Registration Number
- NCT04493541
- Locations
- ๐ฉ๐ช
Local Institution - 0001, Berlin, Germany
ยฉ Copyright 2024. All Rights Reserved by MedPath